Walkersville, MD (USA) / Basel, Switzerland, 20 June 2014 – Lonza introduced its new L7™ hiPSC Reprogramming and hPSC Culture System for basic stem-cell research, disease modeling, drug development and regenerative medicine at ISSCR, in Vancouver, Canada. Lonza’s highlighted offering includes innovative tools to simplify and streamline the stem-cell culturing and reprogramming workflow. The novel L7™ Culture System supports the generation of reproducible, clinically relevant data as a solid basis for more efficient drug development and accelerated progress in regenerative medicine.
The L7™ stem-cell reprograming and culture system includes seven key components that are aligned and function as a robust workflow:
1. Primary cells, including disease phentoypes 2. Nucleofector™ Technology 3. hPSC Reprogramming Kits 4. hPSC Medium 5. hPSC Matrix 6. hPC Passaging Solution 7. hPSC Cryosolution
This novel culture system is the only available complete solution for the generation of induced pluripotent stem-cells (iPSCs), the maintenance of human embryonic stem-cells (hESCs) and iPSCs under defined, xeno-free conditions. The culture system allows for every other day feeding and supports long term culture and maintenance of hPSCs. The L7™ System thus provides a seamless transition from the lab bench to clinical development applications. Highlighting their new advancements, Lonza will host the Innovation Showcase “Bridging Research to Therapy: Novel iPSC Tools and Technologies” on Thursday, 19 June, 11:30am - 12:30 pm, in the West Ballroom B, Level # 1. During the one hour symposium, three renowned speakers will describe different approaches to overcome hiPSC challenges. To learn more about L7™ and Lonza’s Innovation Showcase, visit www.lonza.com/isscr.
Speakers and topics are:
• “From the Nobel Prize to the Clinic: One Step Closer to iPSC-Based Therapies”, Behnam Ahmadian Baghbaderani, Ph.D., Lonza Walkersville, Cell Therapy Development Services
• “Lonza L7™ Reprogramming and Cell Culture System – A Case Study”, Yu-Chieh Wang, Ph.D., Senior Research Associate, Center for Regenerative Medicine, The Scripps Research Institute
• “Highly Efficient and Specific Human Genome Editing in iPSCs Using CRISPR-Cas9 System”, Linzhao Cheng, Ph.D., Professor of Medicine and Oncology Stem Cell Program in the Institute for Cell Engineering, Johns Hopkins School of Medicine
Lonza invites attendees to visit the ISSCR Lonza Booth 1000 to learn more about products and services that support stem-cell researchers from the laboratory bench to clinical applications.
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza’s stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at www.lonza.com.
Contact Information
Lonza Cologne GmbH
Marketing Communications and Product PR
Corinna König-Wildförster
Phone: +49 221 99199 464
pr.cologne@lonza.com
Lonza Group Ltd
Head External Communications
Constance Ward
constance.ward@lonza.com
Phone +41 61 316 8840
Help employers find you! Check out all the jobs and post your resume.
